Literature DB >> 22946730

Causes of status epilepticus.

Eugen Trinka1, Julia Höfler, Alexander Zerbs.   

Abstract

Status epilepticus (SE) is the most extreme form of epilepsy. It describes a prolonged seizure that may occur in patients with previous epilepsy or in acute disorders of the central nervous system. It is one of the most common neurologic emergencies, with an incidence of up to 41 per 100,000 per year and an estimated mortality is 20%. The three major determinants of prognosis are the duration of SE, patient age, and the underlying cause. Common and easily recognized causes of SE include cerebrovascular disorders, brain trauma, infections, and low antiepileptic drug levels in patients with epilepsy. Less common causes present a clinical and diagnostic challenge, but are major determinants of prognosis. Among them, inflammatory causes and inborn errors of metabolism have gained wide interest; recent insights into these causes have contributed to a better understanding of the pathophysiology of SE and its appropriate treatment. This review focuses on the different etiologies of SE and emphasizes the importance of prompt recognition and treatment of the underlying causes. Wiley Periodicals, Inc.
© 2012 International League Against Epilepsy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22946730     DOI: 10.1111/j.1528-1167.2012.03622.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  34 in total

Review 1.  Status epilepticus: an update.

Authors:  Panayiotis N Varelas; Marianna V Spanaki; Marek A Mirski
Journal:  Curr Neurol Neurosci Rep       Date:  2013-07       Impact factor: 5.081

Review 2.  Awareness and current knowledge of epilepsy.

Authors:  Asmat Ullah Khan; Muhammad Akram; Muhammad Daniyal; Naheed Akhter; Muhammad Riaz; Naheed Akhtar; Mohammad Ali Shariati; Fozia Anjum; Samreen Gul Khan; Abida Parveen; Saeed Ahmad
Journal:  Metab Brain Dis       Date:  2019-10-11       Impact factor: 3.584

3.  Evaluation of a clinical tool for early etiology identification in status epilepticus.

Authors:  Jong Woo Lee; Andrea O Rossetti; Vincent Alvarez; M Brandon Westover; Frank W Drislane; Barbara A Dworetzky; David Curley
Journal:  Epilepsia       Date:  2014-11-10       Impact factor: 5.864

4.  Repeated low-dose kainate administration in C57BL/6J mice produces temporal lobe epilepsy pathology but infrequent spontaneous seizures.

Authors:  Anthony D Umpierre; Isaiah V Bennett; Lismore D Nebeker; Thomas G Newell; Bruce B Tian; Kyle E Thomson; H Steve White; John A White; Karen S Wilcox
Journal:  Exp Neurol       Date:  2016-02-16       Impact factor: 5.330

5.  Behavioral assessment of NIH Swiss mice acutely intoxicated with tetramethylenedisulfotetramine.

Authors:  Brenna M Flannery; Jill L Silverman; Donald A Bruun; Kyle R Puhger; Mark R McCoy; Bruce D Hammock; Jacqueline N Crawley; Pamela J Lein
Journal:  Neurotoxicol Teratol       Date:  2014-11-08       Impact factor: 3.763

Review 6.  Neuromonitoring in the ICU.

Authors:  Andrew C Schomer; Khalid Hanafy
Journal:  Int Anesthesiol Clin       Date:  2015

7.  Oxidative Stress Contributes to Status Epilepticus Associated Mortality.

Authors:  Jennifer N Pearson-Smith; Li-Ping Liang; Shane D Rowley; Brian J Day; Manisha Patel
Journal:  Neurochem Res       Date:  2017-05-02       Impact factor: 3.996

8.  Status epilepticus: Using antioxidant agents as alternative therapies.

Authors:  Liliana Carmona-Aparicio; Cecilia Zavala-Tecuapetla; María Eva González-Trujano; Aristides Iii Sampieri; Hortencia Montesinos-Correa; Leticia Granados-Rojas; Esaú Floriano-Sánchez; Elvia Coballase-Urrutía; Noemí Cárdenas-Rodríguez
Journal:  Exp Ther Med       Date:  2016-08-23       Impact factor: 2.447

9.  Serotonin 1A receptor inhibits the status epilepticus induced by lithium-pilocarpine in rats.

Authors:  Yi Yang; Yi Guo; Yifang Kuang; Shan Wang; Yan Jiang; Yao Ding; Shuang Wang; Meiping Ding
Journal:  Neurosci Bull       Date:  2014-01-15       Impact factor: 5.203

Review 10.  NMDA antagonists for refractory seizures.

Authors:  F A Zeiler; J Teitelbaum; L M Gillman; M West
Journal:  Neurocrit Care       Date:  2014-06       Impact factor: 3.210

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.